^
Association details:
Evidence:
Evidence Level:
Sensitive: D – Preclinical
New
Source:
Title:

792 Givastomig, a novel Claudin18.2/4–1BB bispecific antibody, exerts bystander tumor-killing and synergistic anti-tumor activity with therapeutics in 1L/2L treatment for gastric cancer

Published date:
11/04/2023
Excerpt:
Givastomig elicited tumor-killing activity against CLDN18.2-positive MKN-45#14 and MKN-45#18 cells but not CLDN18.2-negative MKN-45 cells. Interestingly, bystander tumor-killing was observed in a mixture of MKN-45#14 cells and MKN-45 cells at various ratios in the presence of givastomig.
DOI:
10.1136/jitc-2023-SITC2023.0792
Evidence Level:
Sensitive: D – Preclinical
Title:

CLDN18.2 and 4-1BB bispecific antibody givastomig exerts antitumor activity through CLDN18.2-expressing tumor-directed T-cell activation

Published date:
06/26/2023
Excerpt:
Furthermore, in humanized 4-1BB transgenic mice inoculated with human CLDN18.2-expressing tumor cells, givastomig/ABL111 induced a localized immune activation in tumor as evident by the increased ratio of CD8+/regulatory T cell, leading to the superior antitumor activity and long-lasting memory response against tumor rechallenge.
DOI:
10.1136/jitc-2023-006704